NCT06162221 · Revolution Medicines, Inc.
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
What this study is about
The purpose of this platform study is to evaluate the safety, tolerability, how the drug moves through the body (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a treatment given alone or combined with Standard(s) of Care (SOC) or with each other.
View original scientific description
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
Interventions
DRUG
RMC-6291
Oral tablet
DRUG
RMC-6236
Oral tablet
DRUG
Pembrolizumab
IV Infusion
DRUG
Cisplatin
IV Infusion
DRUG
Carboplatin
IV Infusion
DRUG
Pemetrexed
IV infusion
DRUG
RMC-9805
Oral Tablet
Primary outcome measures
Adverse events
Time frame: Up to 5 years
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs
Dose limiting toxicities
Time frame: 21 days
Number of participants with dose limiting toxicities
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- All Patients (unless otherwise noted):
- ≥ 18 years of age
- ECOG PS is 0 to 1
- Adequate organ function as outlined by the study
- Received prior standard therapy appropriate for tumor type and stage
- Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)
- Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)
- Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Exclusion criteria
- All Patients:
- Primary central nervous system (CNS) tumors
- Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
- Major surgery \< 28 days of first dose
- Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids Other inclusion/exclusion criteria may apply.
Where
- Gilbert, Arizona
- Duarte, California
- Irvine, California
- Sacramento, California
- San Diego, California
- San Francisco, California
- Stanford, California
- Colorado Springs, Colorado
- Washington D.C., District of Columbia
- Plantation, Florida
- Saint Augustine, Florida
- Tampa, Florida
And 14 more locations — see the full list below.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 30, 2026 · Source of record for eligibility and locations